Inhibiting Signaling that Drives Growth of Rare Malformations

Venous and lymphatic malformations are types of congenital vascular anomalies that are present at birth. These malformations can cause a number of complications including pain, bleeding, and impairment of the affected area. Current treatments options are limited and there are no drugs approved for these conditions. Venthera, a BridgeBio affiliate, is developing a topical gel for the treatment of venous and lymphatic malformations that targets signaling pathways that drive them. We spoke to Thom Rossi, CEO of Venthera, about the company’s lead experimental therapy, its first-in-man-trial, and how it is leveraging the resources of BridgeBio.